Fig 1.
Structure of the Markov cohort model.
Arrows to the health state “dead” excluded for simplification. Fx, fracture; Vert, vertebral. Transition to death can occur from any state.
Table 1.
Relative risks of fractures used in the model.
Table 2.
Health-related quality of life, utilities, and drug, treatment monitoring/administration, direct medical costs.
Table 3.
Base case lifetime cost-effectiveness results.
Fig 2.
Scatter plot of probabilistic results (incremental).
LY, life year.
Fig 3.
Cost-effectiveness acceptability curves.
LY, life year.
Fig 4.
Tornado diagram of deterministic sensitivity analyses.
Romosozumab/alendronate versus alendronate—discounted incremental net monetary benefit at a threshold of $600,000/QALY. FRAME, FRActure study in postmenopausal woMen with ostEoporosis; BMD, bone mineral density; Fx, fracture; QALY, quality-adjusted life year; RR, relative risk; SD, standard deviation; vert, vertebral.
Table 4.
Scenario analysis results.